Abstract:Ground breaking advances in medicine, driven in part by major technologic developments in molecular biology have led us to a new model for cancer care that has been termed personalized, or precision medicine. Precision medicine is a model for making medical decisions that employs an innovative clinical approach and advanced tumor testing methods that are tailored to understanding an individual patient's tumor biology and the molecular drivers of their disease. This medical model includes a combination of diagnostic testing and specific treatment options that can be offered to patients at presentation and in theory throughout the course of their disease as new mutations arise with the development of disease recurrence. Although the precision medicine model offers incredible potential to transform cancer care, these advances are only meaningful when they reach the correct patients. The evolving paradigm of precision medicine is changing the practice of pathology, and the pathology community needs to be mindful of these changes because every tissue specimen represents a patient's life, and those patients are depending on the pathology community to handle their tissue correctly. The diagnostic tests performed in the pathology laboratory for precision medicine are increasingly complex, and pathologists along with the entire laboratory and clinical communities need to take steps to ensure that the right diagnosis is given to the right patient to inform the right treatment options, at the right time, along every step of the continuum of care for cancer patients. While hormone receptors and human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification have been the mainstay for risk-stratification, and treatment decision making in breast cancer since the early 2000's, the seminal work on gene expression by Perou and colleagues in the early 2000's opened the door for molecular testing in the prognostic and predictive assessment of breast cancer. Molecular testing is now part of the standard of care in the precision medicine model for breast cancer care. In this article, the reader will gain a better understanding of how the lack of standardization of pre-analytic factors has the potential to negatively impact the quality of the tissue specimen for downstream biomarker and molecular testing, which ultimately can negatively affect patient care. The reader will also gain insight into the current climate surrounding molecular testing in breast cancer.

Current Practice and Future Perspectives

Updates on breast biomarkers

[18F]F-Poly(ADP-Ribose) Polymerase Inhibitor Radiotracers for Imaging PARP Expression and Their Potential Clinical Applications in Oncology

Current Applications and Future Perspectives

Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications

Novel applications of molecular imaging to guide breast cancer therapy

The Current and Future Roles of Precision Oncology in Advanced Breast Cancer

Theranostics in breast cancer

Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories

The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years

The role of targeted therapy and biomarkers in breast cancer treatment

Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer

Breast cancer intratumour heterogeneity: current status and clinical implications

Breast Cancer in the 21st Century: Neu Opportunities and Neu Challenges

Optimized biomarker evaluation and molecular testing in the era of breast cancer precision medicine

Breast Cancer Tissue Markers, Genomic Profiling, and Other Prognostic Factors: A Primer for Radiologists

Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies

Breast cancer: an up‐to‐date review and future perspectives

The Role of PET/CT in Breast Cancer

Advances in Radioligand Theranostics in Oncology

Novel Imaging Based Biomarkers in Breast Cancer